Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Hepatocellular 17Stomach Neoplasms 8Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Rectal Neoplasms 5Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 3Nasopharyngeal Carcinoma 3Esophageal Neoplasms 3Uterine Cervical Neoplasms 2Solid Tumor 2Recurrence 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Endometrial Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Small Cell Lung Carcinoma 1Resectable NSCLC 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasms, Unknown Primary 1Neoplasms 1Metastatic Gastroesophageal Junction Adenocarcinoma 1Meningeal Carcinomatosis 1MSI-H 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1

Interventions

Cyclophosphamide 28Temozolomide 25Irinotecan 21dinutuximab 20Topotecan 15Magnetic Resonance Spectroscopy 13Specimen Handling 12Biopsy 12naxitamab 11Granulocyte-Macrophage Colony-Stimulating Factor 113-Iodobenzylguanidine 11Vincristine 10Etoposide 10sargramostim 9Melphalan 9Isotretinoin 9fludarabine 8X-Rays 8Colony-Stimulating Factors 8Carboplatin 8etoposide phosphate 7Phantoms, Imaging 7Doxorubicin 7fludarabine phosphate 6Stem Cell Transplantation 6Nuclear Medicine Department, Hospital 6Eflornithine 6Thiotepa 5Granulocyte Colony-Stimulating Factor 5Filgrastim 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × sintilimab × 1 year × Clear all
NCT06013618 2025-06-17

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Sun Yat-sen University

Phase 2 Recruiting
120 enrolled
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡